Jump to navigation (n)
Jump to content
Sitemap

About Us
- Back
- Overview
- Our Team
- Our Values
Patients & Physicians
Pipeline
Media Center
Contact

December 05, 2022

Ninerafaxstat to Provide Optimal Ventricular Energetics in HCM: IMPROVE-HCM

Home
Media Center

Share on

Share on X.com
Share on Facebook
Share on LinkedIn
Send URL via Email

Download the presentation

Explore further

April 08, 2024

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24

April 08, 2024

ACC.24 Late-Breaking IMPROVE-HCM Presentation

April 08, 2024

Dr. Maron and Dr. Gibson Discuss Ninerafaxstat and IMPROVE-HCM

April 08, 2024

Journal of the American College of Cardiology

About Us
Patients & Physicians
Pipeline
Media Center
Contact

© Imbria 2024
Terms of Use
Privacy Policy

LinkedIn

Home
About Us
- Back
- About Us
- About Us overview
- Our Team
- Our Values
Patients & Physicians
- Back
- Patients & Physicians
- Patients & Physicians overview
- Clinical Trials
- Non-obstructive Hypertrophic Cardiomyopathy
- Stable Angina
- Heart Failure
Pipeline
- Back
- Pipeline
- Pipeline overview
- Ninerafaxstat
Media Center
Contact

Search

You Are About to Leave Imbria Pharmaceuticals

The appearance of external hyperlinks does not constitute endorsement by Imbria Pharmaceuticals of the linked websites, or the information, products or services contained therein.